Cue biopharma reports second quarter 2021 results, recent data updates of cue-101 phase 1 dose escalation and expansion study, platform progress and business highlights

Cambridge, mass., aug. 17, 2021 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted t cells within the patient's body, provided a business and clinical progress update for the second quarter 2021.
CUE Ratings Summary
CUE Quant Ranking